Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) was down 8.9% on Monday . The stock traded as low as $1.32 and last traded at $1.33. Approximately 579,108 shares traded hands during mid-day trading, an increase of 171% from the average daily volume of 213,869 shares. The stock had previously closed at $1.46.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Telomir Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Telomir Pharmaceuticals Stock Down 8.9%

The firm’s fifty day moving average price is $1.40 and its 200 day moving average price is $1.49. The stock has a market cap of $45.73 million, a PE ratio of -3.59 and a beta of -0.46.

Telomir Pharmaceuticals (NASDAQ:TELO) last posted its earnings results on Monday, November 10th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.04. As a group, analysts anticipate that Telomir Pharmaceuticals, Inc. will post -0.4 earnings per share for the current fiscal year.

Institutional Trading of Telomir Pharmaceuticals

Hedge funds have recently modified their holdings of the company. HighTower Advisors LLC purchased a new stake in shares of Telomir Pharmaceuticals in the first quarter valued at $139,000. Y Intercept Hong Kong Ltd bought a new position in Telomir Pharmaceuticals during the 2nd quarter valued at about $81,000. Nuveen LLC purchased a new stake in Telomir Pharmaceuticals in the 1st quarter worth about $81,000. Praetorian Wealth Management Inc. bought a new stake in Telomir Pharmaceuticals in the third quarter worth about $28,000. Finally, OneDigital Investment Advisors LLC boosted its position in shares of Telomir Pharmaceuticals by 64.3% during the third quarter. OneDigital Investment Advisors LLC now owns 23,000 shares of the company’s stock valued at $32,000 after buying an additional 9,000 shares during the period.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.